Contraception
Volume 73, Issue 3 , Pages 215-222 , March 2006

Contraception: an international perspective

Received 24 August 2005 ,Accepted 26 August 2005.

References 

  1. Population Reference Bureau Staff . Transitions in world population. Popul Bull. 2004;1–43
  2. In: World Population Data Sheet of the Population Reference Bureau. Washington (DC): Population Reference Bureau; 2004;p. 1–17
  3. Bongaarts J, Watkins C. Social interactions and contemporary fertility transitions. Popul Dev Rev. 1996;22:639–682
  4. Bongaarts J, Amin S. Prospects for fertility decline and implications for population growth in South Asia. In:  Sathar Z,  Phillips J editor. Fertility transition in South Asia. Oxford: Oxford University Press; 2001;p. 401–422
  5. Johansson ED. The return of the pharmaceutical industry to the market of contraception. Steroids. 2000;65:709–711
  6. Daulaire N, Leidle P, Mackin L, Murphy C, Stark L. In: Promises to keep: the toll of unintended pregnancies on women's lives in the developing world. Washingtoon (DC): Global Health Council; 2002;p. 1–48
  7. United Nations . In: World Contraceptive Use 2003. New York: United Nations, Dept of Economic and Social Affairs, Population Division; 2004;p. 1
  8. Bongaarts J, Johansson E. Future trends in contraceptive prevalence and method mix in the developing world. Stud Fam Plann. 2002;33:24–36
  9. Nass S, Strauss J. New frontiers in contraceptive research: a blueprint for action. Washington (DC): Institute of Medicine National Academy Press; 2004;
  10. Bajos N, Leridon H, Goulard H, Oustry P, Job-Spira N. Contraception: from accessibility to efficiency. Hum Reprod. 2003;18:994–999
  11. Harrison PF, Rosenfield A. Contraceptive research and development: looking to the future. Washington (DC): Institute of Medicine. National Academy Press; 1996;
  12. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids. 2000;65:699–702
  13. Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception. 2001;64:43–49
  14. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58(Suppl):91S–97S
  15. Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65:629–636
  16. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283
  17. Massai MR, Diaz S, Quinteros E, et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception. 2001;64:369–376
  18. Sivin I, Mishell DR, Alvarez F, et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception. 2005;71:122–129
  19. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol. 2004;190:S54–S59
  20. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16:469–475
  21. Massai R, Diaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids. 2000;65:703–707
  22. Brache V, Mishell DR, Lahteenmaki P, et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception. 2001;63:257–261
  23. Harwood B, Mishell DR. Contraceptive vaginal rings. Semin Reprod Med. 2001;19:381–390
  24. Lahteenmaki P, Jukarainen H. Novel delivery systems in contraception. Br Med Bull. 2000;56:739–748
  25. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril. 2001;75:865–870
  26. Sitruk-Ware R. Delivery options for contraceptives. Drug Discov Today. 2005;10:977–985
  27. Weisberg E, Fraser IS, Mishell DR, Lacarra M, Darney P, Jackanicz TM. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception. 1999;59:305–310
  28. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–242
  29. Fraser IS, Weisberg E, Brache V, et al. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen–ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception. 2005;72:40–45
  30. Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril. 2002;77:S3–S12
  31. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol. 2001;98:799–805
  32. Zieman M. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra). Fertil Steril. 2002;77:S1–S2
  33. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril. 2002;77:S27–S31
  34. Croxatto HB, Zepeda A. Transdermal contraceptive systems: innovative technology for the twenty-first century. In:  Sitruk-Ware R,  Bardin W editor. Contraception. Newer pharmacological agents, devices, and delivery systems. New York: Marcel Dekker, Inc; 1992;p. 101–115
  35. Sitruk-Ware R, Small M, Kumar N, Tsong YY, Sundaram K, Jackanicz T. Nestorone: clinical applications for contraception and HRT. Steroids. 2003;68:907–913
  36. Anderson RA, Baird DT. Male contraception. Endocr Rev. 2002;23:735–762
  37. Kamischke A, Nieschlag E. Progress towards hormonal male contraception. Trends Pharmacol Sci. 2004;25:49–57
  38. von Eckardstein S, Noe G, Brache V, et al. International Committee for Contraception Research, The Population Council. clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88:5232–5239
  39. Swerdloff RS, Bagatell CJ, Wang C, et al. Suppression of spermatogenesis in man induced by Nal–Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 1998;83:3527–3533
  40. Cheng CY, Mo M, Grima J, et al. Indazole carboxylic acids in male contraception. Contraception. 2002;65:265–268
  41. Grima J, Silvestrini B, Cheng CY. Reversible inhibition of spermatogenesis in rats using a new male contraceptive, 1-(2,4-dichlorobenzyl)-indazole-3-carbohydrazide. Biol Reprod. 2001;64:1500–1508
  42. Eddy EM, Toshimori K, O'Brien DA. Fibrous sheath of mammalian spermatozoa. Microsc Res Tech. 2003;61:103–115
  43. Heinemann K, Saad F, Wiesemes M, Heinemann LA. Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J Androl. 2005;26:155–162
  44. Glasier AF, Anakwe R, Everington D, et al. Would women trust their partners to use a male pill?. Hum Reprod. 2000;15:646–649
  45. Croxatto HB. Progestin implants for female contraception. Contraception. 2002;65:15–19

PII: S0010-7824(05)00326-4

doi: 10.1016/j.contraception.2005.08.019

Contraception
Volume 73, Issue 3 , Pages 215-222 , March 2006

Article Tools

* Image Usage & Resolution